Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Zalmai Hakimi, Con Kelleher, Samuel Aballéa, Khaled Maman, Jameel Nazir, Colette Mankowski & Isaac Odeyemi. (2018) Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK. Journal of Market Access & Health Policy 6:1.
Read now
Read now
Konstantinos Giannitsas & Anastasios Athanasopoulos. (2015) A review of cost–effectiveness comparisons for overactive bladder treatments: which is the most cost-effective for improving quality of life?. Expert Review of Pharmacoeconomics & Outcomes Research 15:3, pages 413-423.
Read now
Read now
J. Nazir & W.M. Hart. (2014) The cost-effectiveness of solifenacin vs. trospium in the treatment of patients with overactive bladder in the German National Health Service. Journal of Medical Economics 17:6, pages 408-414.
Read now
Read now
Warren Mark Hart, Paul Abrams, Vicki Munro, Peny Retsa & Jameel Nazir. (2013) Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom. Journal of Medical Economics 16:10, pages 1246-1254.
Read now
Read now
Edward P. Armstrong, Daniel C. Malone & Cat N. Bui. (2012) Cost-effectiveness analysis of anti-muscarinic agents for the treatment of overactive bladder. Journal of Medical Economics 15:sup1, pages 35-44.
Read now
Read now
Bram G. Verheggen, Richard Lee, Michelle M. Lieuw On, Maarten J. Treur, Marc F. Botteman, Steven A. Kaplan & Jeffrey N. Trocio. (2012) Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder. Journal of Medical Economics 15:3, pages 586-600.
Read now
Read now
Emilio Sacco, Daniele Tienforti, Alessandro D’Addessi, Francesco Pinto, Marco Racioppi, Angelo Totaro, Daniele D’Agostino, Francesco Marangi & Pierfrancesco Bassi. (2010) Social, economic, and health utility considerations in the treatment of overactive bladder. Open Access Journal of Urology 2, pages 11-24.
Read now
Read now
S. Herschorn, C. Vicente & C. Piwko. (2010) Canadian cost-effectiveness analysis of solifenacin compared to oxybutynin immediate-release in patients with overactive bladder. Journal of Medical Economics 13:3, pages 508-515.
Read now
Read now
Dudley Robinson & Linda Cardozo. (2009) Solifenacin: pharmacology and clinical efficacy. Expert Review of Clinical Pharmacology 2:3, pages 239-253.
Read now
Read now
Lorenzo Pradelli & Sergio Iannazzo. (2009) Solifenacin in the treatment of overactive bladder syndrome in Italian patients: pharmacoeconomic evaluation. Journal of Medical Economics 12:1, pages 25-35.
Read now
Read now
Articles from other publishers (15)
Yuriko Yamanishi, Tomonori Yamanishi, Hakujyu Tajima & Shunya Ikeda. (2018) Mirabegron or tolterodine for the treatment of overactive bladder in Japan: Which drug is more cost‐effective as the first‐line treatment?. International Journal of Urology 25:10, pages 863-870.
Crossref
Crossref
Sonya J. Snedecor. (2018) Review of Economic Value Drivers of the Treatment of Overactive Bladder. PharmacoEconomics 36:9, pages 1083-1092.
Crossref
Crossref
Carlos Crespo, Pedro Blasco, Marcelo Guigini & Jordi Galván. (2018) Clinical and Economic Evaluation of Transdermal Oxybutynin in the Treatment of Overactive Bladder in Spain. Journal of Health Economics and Outcomes Research 5:2, pages 194-205.
Crossref
Crossref
C. Guillot-Tantay, E. Chartier-Kastler, Q. Manach, M.-A. Perrouin-Verbe, P. Denys & V. Phé. (2017) Évaluation médico-économique des traitements urologiques chez les patients blessés médullaires : revue de la littérature. Progrès en Urologie 27:1, pages 3-9.
Crossref
Crossref
Suneetha Rachaneni, Shanteela McCooty, Lee J Middleton, Victoria L Parker, Jane P Daniels, Arri Coomarasamy, Tina S Verghese, Moji Balogun, Ilias Goranitis, Pelham Barton, Tracy E Roberts, Jonathan J Deeks & Pallavi Latthe. (2016) Bladder ultrasonography for diagnosing detrusor overactivity: test accuracy study and economic evaluation. Health Technology Assessment 20:7, pages 1-150.
Crossref
Crossref
Samuel Aballéa, Khaled Maman, Katia Thokagevistk, Jameel Nazir, Isaac A. O. Odeyemi, Zalmai Hakimi, Andy Garnham & Mondher Toumi. (2014) Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom. Clinical Drug Investigation 35:2, pages 83-93.
Crossref
Crossref
Dudley Robinson, Ilias Giarenis & Linda Cardozo. (2013) The medical management of refractory Overactive Bladder. Maturitas 74:4, pages 386-390.
Crossref
Crossref
Fredrik O.L. Nilsson, Love Linnér, Eva Samuelsson & Ian Milsom. (2012) Cost-effectiveness analysis of newer anticholinergic drugs for urinary incontinence vs oxybutynin and no treatment using data on persistence from the Swedish prescribed drug registry. BJU International 110:2, pages 240-246.
Crossref
Crossref
Priya Madhuvrata, June D Cody, Gaye Ellis, G Peter Herbison & E. Jean C Hay-Smith. (2012) Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Salvador Arlandis-Guzman, Carlos Errando-Smet, Jeffrey Trocio, Daniel Arumi & Javier Rejas. (2011) Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: A decision-tree model. BMC Urology 11:1.
Crossref
Crossref
Dudley Robinson & Linda Cardozo. (2011) Solifenacin for the treatment of overactive bladder. Therapy 8:6, pages 691-701.
Crossref
Crossref
Emilio Sacco, Riccardo Bientinesi, Francesco Marangi, Alessandro D'addessi, Marco Racioppi, Gaetano Gulino, Francesco Pinto, Angelo Totaro & Pierfrancesco Bassi. (2011) Overactive Bladder Syndrome: The Social and Economic Perspective. Urologia Journal 78:4, pages 241-256.
Crossref
Crossref
C. C. Sexton, S. M. Notte, C. Maroulis, R. R. Dmochowski, L. Cardozo, D. Subramanian & K. S. Coyne. (2011) Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. International Journal of Clinical Practice 65:5, pages 567-585.
Crossref
Crossref
Linda Cardozo, Andrew Thorpe, Juliet Warner & Manpreet Sidhu. (2010) The cost‐effectiveness of solifenacin vs fesoterodine, oxybutynin immediate‐release, propiverine, tolterodine extended‐release and tolterodine immediate‐release in the treatment of patients with overactive bladder in the UK National Health Service. BJU International 106:4, pages 506-514.
Crossref
Crossref
. (2013) Solifenacin economically dominant in OAB. PharmacoEconomics & Outcomes News 563:1, pages 1-1.
Crossref
Crossref